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Abstract 15 
We previously showed that soluble nitroxides (nitric oxide analogues) mimicked the 16 
well-established ability of nitric oxide to cause biofilm dispersal and further showed that 17 
these compounds could prevent biofilm formation. Here we investigated the effect of the 18 
nitroxide carboxy-TEMPO in combination with sub µg/ml concentrations of 19 
ciprofloxacin on pre-formed flow cell biofilms formed by Gram-negative bacteria. 20 
Combination therapy led to substantial eradication of existing biofilms formed by 21 
Pseudomonas aeruginosa PA14 (99.3%) and Escherichia coli O157 (93%).  22 
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MAIN TEXT 23 
Biofilms are multicellular structures composed of bacterial subpopulations embedded 24 
in a complex extracellular matrix mainly consisting of polysaccharides (de la Fuente-25 
Núñez et al., 2013b). Many species of bacteria are capable of forming biofilms, both in 26 
nature and in clinical settings, particularly during infections due to implant surgery. This 27 
bacterial behavior shows high antibiotic resistance and is a major issue in the clinic. 28 
Indeed, no antimicrobial agent has been developed that efficiently targets bacterial 29 
biofilms. At the late stages of the biofilm developmental cycle, cells that disperse from 30 
mature biofilms can then differentiate back to the planktonic state, which enables bacteria 31 
to undergo swimming motility, and potentially forming new biofilms in a new infection 32 
site (McDougald et al., 2011).  A variety of different signals can induce dispersal 33 
including nitric oxide (NO) (Barraud N. et al., 2006; Barraud N. et al., 2009; Schreiber et 34 
al., 2011). Indeed a low non-toxic concentration of NO can turn biofilm cells into free-35 
swimming cells which thereby increases their susceptibility of bacteria to antimicrobials 36 
(Barraud N. et al., 2006; McDougald et al., 2011). As the delivery of gaseous nitric oxide 37 
can be challenging, an alternative strategy involving the use of nitroxides (sterically 38 
hindered versions of nitric oxide) was recently investigated. Nitroxides were shown to 39 
both inhibit P. aeruginosa bacterial biofilm formation and disperse pre-existing biofilms. 40 
(de la Fuente-Núñez et al., 2013a). Nitroxides (aminoxyls) are persistent and stable free-41 
radical species containing a univalent oxygen atom bound to a di-substituted nitrogen 42 
atom (Likhtenshtein et al., 2008). As the structures of both nitric oxide and nitroxides 43 
contain an unpaired electron which is delocalized over the nitrogen-oxygen bond, 44 
nitroxides can be considered sterically hindered versions of nitric oxide. Furthermore, the 45 
biological effects of nitroxides can often be explained by their nitric oxide-mimetic 46 
properties, with both compounds acting as efficient scavengers of protein-derived 47 
radicals and possessing superoxide dismutase mimetic properties (Lam et al., 2008) 48 
Many nitroxides, however, have the additional benefit of existing as crystalline solids at 49 
room temperature and are therefore much easier to handle and deliver than gaseous nitric 50 
oxide. In this work, we aimed to investigate whether nitroxides could be used to reduce 51 
the well-known (de la Fuente-Núñez et al., 2013b) resistance of biofilms to antibiotic 52 
treatment. 53 
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The nitroxide carboxy-TEMPO (4-carboxy-2,2,6,6-tetramethylpiperidine 1-oxyl, Fig. 54 
1 top panel), was obtained commercially (382000, Sigma Aldrich) and prepared as 55 
previously described (Fairfull-Smith KE  et al., 2009). We recently showed that the 56 
relative levels of NO play an important role in P. aeruginosa biofilm physiology, as NO 57 
production was shown to be necessary for biofilm formation and an excess of NO (or 58 
nitroxide) induced biofilm dispersion in pre-formed biofilms (de la Fuente-Núñez et al., 59 
2013). Our previous study identified carboxy-TEMPO as the optimal biofilm-dispersing 60 
mimetic among the different nitroxides tested, since it prevented biofilm formation and 61 
led to dispersal of pre-existing biofilms of P. aeruginosa PA14 (de la Fuente-Núñez et 62 
al., 2013). We reasoned that a biofilm dispersant might make biofilms more susceptible 63 
to antibiotic inhibition. Therefore we investigated the effect, on 2-day old P. aeruginosa 64 
PA14 (Breidenstein et al., 2011) and Escherichia coli O157 (Chase-Topping et al., 2008) 65 
biofilms, of the combination of sub-inhibitory levels of carboxy-TEMPO with the 66 
conventional antibiotic ciprofloxacin.  67 
To evaluate the dispersal ability of the nitroxide compound, biofilms were grown in 68 
BM2 minimal medium supplemented with 0.4% of glucose for 48 h in a flow cell system, 69 
as previously described (de la Fuente-Núñez et al., 2013a). Flow cell chambers were 70 
inoculated by injecting 400 µL of an overnight culture diluted to an OD600 of 0.05. After 71 
inoculation, chambers were left without flow for 2 h to enable adherence, after which 72 
medium was pumped through the system at a constant rate of 0.5 rpm (2.4 ml/h). At the 73 
end of the second day, biofilms were exposed to 20 µM of compound carboxy-TEMPO 74 
for 24 h. Staining and visualization of the resulting biofilms was performed using the 75 
LIVE/DEAD BacLight Bacterial Viability kit (Molecular Probes, Eugene, OR) and a 76 
confocal laser scanning microscope (Olympus, Fluoview FV1000) as previously 77 
described (de la Fuente-Núñez et al., 2013a). 78 
P. aeruginosa PA14 and E. coli O157 biofilms formed in flow cell chambers 79 
appeared thick and well-structured with multiple microcolonies. Since dispersed cells are 80 
planktonic, we assumed we would see synergy of nitroxides with bactericidal antibiotics, 81 
despite their generally poor activity vs. biofilms, however in preliminary 96-well plate 82 
synergy assays, we only observed promising results with the antibiotic ciprofloxacin. The 83 
fluoroquinolone ciprofloxacin, which is commonly used to treat P. aeruginosa infections, 84 
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is an antibiotic acting on cell division by inhibition of DNA gyrases. We treated pre-85 
formed biofilms grown in flow cells with concentrations corresponding to the Minimal 86 
Inhibition Concentration (MIC) of ciprofloxacin for P. aeruginosa PA14 (320 ng/ml) and 87 
E. coli O157 (20 ng/ml). Some dead cells (stained yellow) were observed for the treated 88 
P. aeruginosa biofilm although the thickness was the same (Fig. 1 top panel), while 89 
ciprofloxacin treated biofilms formed by E. coli remained almost identical to untreated 90 
biofilms (Fig. 1 bottom panel).  In contrast, carboxy-TEMPO exhibited stand-alone 91 
activity in causing dispersal of pre-existing biofilms in both Gram-negative bacteria, 92 
consistent with our previous work on Pseudomonas (de la Fuente-Núñez et al., 2013a). 93 
Indeed, thinner biofilms were observed, thus indicating that biofilm thickness was 94 
decreased compared to the untreated controls (Fig. 1). By using Imaris software (Bitplane 95 
AG) to calculate the biofilm biovolume (µm3), it was shown that after treatment with 96 
carboxy-TEMPO, the total biofilm biovolume of P. aeruginosa biofilms treated with 20 97 
µM of carboxy-TEMPO showed a decrease of 60% in biofilm biovolume compared to 98 
the untreated controls (p<0.05) (Table 1). We found that this effect was, at least in part, 99 
due to increased dispersal of bacteria from biofilms upon treatment with carboxy-100 
TEMPO (Fig. S2). To assay for dispersed cells from P. aeruginosa biofilms, aliquots of 101 
30-min flow rate effluent cells were collected at the designated times (0, 3, 6 and 24 h) 102 
and centrifuged, the pellet was then resuspended in 1 ml of LB and serially diluted 10-103 
fold, and 100-μl portions from serial dilutions of these aliquots were plated onto LB agar 104 
plates. The plates were incubated at 37°C overnight, and colony counts were performed 105 
to obtain the numbers of CFU/ml at each time point. The experiment was repeated at least 106 
twice. On the other hand, E. coli biofilms was reduced to 29% cf. the biofilm biovolume 107 
of untreated biofilms (Table 1). However, due to variability among samples, these results 108 
were not significant (p>0.05). Interestingly, carboxy-TEMPO did not trigger cell death in 109 
either P. aeruginosa or E. coli biofilms (Fig. 1). Conversely, at the concentrations tested, 110 
we observed no anti-biofilm effect of carboxy-TEMPO on S. aureus MRSA biofilms 111 
(Figure S1) thus suggesting that the activity of this nitroxide might be limited to Gram-112 
negative organisms. 113 
 Next, we investigated the activity of carboxy-TEMPO in combination with 114 
ciprofloxacin on pre-formed biofilms. Two day-old biofilms were exposed to the 115 
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combined treatment of ciprofloxacin (at its MIC for each bacterial species) and carboxy-116 
TEMPO (20 µM) for 24 h. Examination of the flow cells using confocal microscopy at 117 
the end of the experiment revealed that biofilm thickness and the total number of attached 118 
cells had been substantially decreased (Fig. 1). In fact, on average, the total P. aeruginosa 119 
biofilm biovolume in samples treated with carboxy-TEMPO plus ciprofloxacin was 120 
decreased by 99.3% compared to untreated biofilms (Table 1), cf. treatment with 121 
carboxy-TEMPO alone resulted in a 60% decrease in total biofilm biovolume compared 122 
to untreated samples (Table 1). For E. coli biofilms, carboxy-TEMPO combined with 123 
ciprofloxacin reduced the total biofilm biovolume (by 87% relative to control) and 124 
47±6% of the remaining 13% of biofilm biovolume was composed of dead cells, 125 
compared to >2% in the untreated samples (Table 1), indicating a overall decrease of 126 
93% in live cells. Thus, the combination of nitroxide plus ciprofloxacin led to an almost 127 
complete eradication of mature biofilms formed by P. aeruginosa and E. coli.  128 
In conclusion, the nitroxide carboxy-TEMPO not only caused dispersal of mature 129 
biofilms but also enhanced ciprofloxacin activity in eradicating biofilms formed by 130 
Gram-negative pathogens.  131 
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Table 1.  Total residual biofilm biovolume of treated 2 day-old biofilms relative to 178 
biovolume of untreated biofilms (%). Bacteria were grown as biofilms in a flow cell 179 
system. Treatments [ciprofloxacin (320 ng/ml), nitroxide (20 µM) or both] were added 180 
after 2 days of biofilm growth for a subsequent 24 hours. Calculations were done using 181 
Imaris software. These studies reflect the average of at least 3 replicates with very similar 182 
outcomes. 183 
 TEMPO  Ciprofloxacin + TEMPO 
P. aeruginosa PA14 40% (p<0.05) 0.7% (p<0.01) 
E. coli O157 29% (p>0.05) 13% (p<0.05)  
 184 
 185 
 186 
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Figure 1. Potentiation of ciprofloxacin action against Gram-negative bacterial 187 
biofilms by the nitroxide carboxy-TEMPO. Bacteria were grown as biofilms in a flow 188 
cell system. Treatments (ciprofloxacin (320 ng/ml), nitroxide (20 µM) or both) were 189 
added after 2 days of biofilm growth for a subsequent 24 hours. After 3 days, bacteria 190 
were stained green with the all bacteria stain Syto-9 and red with the dead-bacteria stain 191 
propidium iodide (merge shows as yellow to red) prior to confocal imaging. Each panel 192 
shows reconstructions from the top in the large panel and sides in the right and bottom 193 
panels (xy, yz and xz dimensions). These studies reflect at least 3 replicates with similar 194 
outcomes. Scale bars are 20 µm in all PA14 samples, except the far right image (PA14 195 
treated with both carboxy-TEMPO and ciprofloxacin), which is 30 µm. Scale bars in E. 196 
coli 0157 images correspond to 40 µm with the exception of E. coli 0157 untreated and 197 
the sample treated with ciprofloxacin 20 ng/ml, which are 50 µm.  198 
199 
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